Brief Summary
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanomaa type of cancer that develops from melanocytes, which are the cells that produce pigment generally in the skin (but can develop in other areas of the body).
Intervention / Treatment
- Drug: Darovasertib
Inclusion Criteria:
- Primary localized uveal melanoma requiring either enucleationremoval of the eye and attached optic nerve or plaque brachytherapya type of internal radiation therapy where radioactive material is placed inside or near a tumor to deliver targeted radiation
- Able to dosethe amount of medication taken orally
- ECOG Performance status of 0-1
- No other significant underlying ocular disease
- Adequate organ function
- Not pregnant/nursing or planning to become pregnant. Willing to use birth control.